Tomasz M Beer

List of Publications by Year
in descending order

165 papers	20,165 citations	36691 53 h-index	12272 138 g-index
172 all docs	172 docs citations	172 times ranked	19702 citing authors

#	Article	IF	Citations
1	Delivering exercise medicine to cancer survivors: has COVID-19 shifted the landscape for how and who can be reached with supervised group exercise?. Supportive Care in Cancer, 2022, 30, 1903-1906.	1.0	26
2	Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. European Journal of Cancer, 2022, 160, 24-60.	1.3	12
3	Quality of Life of Prostate Cancer Survivors Participating in a Remotely Delivered Web-Based Behavioral Intervention Pilot Randomized Trial. Integrative Cancer Therapies, 2022, 21, 153473542110635.	0.8	4
4	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 115-141.	0.9	51
5	Short-term ADT and Dose-escalated IMRT in Patients With Intermediate-risk Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2022, 45, 190-195.	0.6	2
6	Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. European Journal of Cancer, 2022, 170, 285-295.	1.3	9
7	The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. Cancers, 2021, 13, 3501.	1.7	50
8	Study protocol for the Exercising TogetherÂ© trial: a randomized, controlled trial of partnered exercise for couples coping with cancer. Trials, 2021, 22, 579.	0.7	7
9	Lutetium-177â€“PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2021, 385, 1091-1103.	13.9	1,042
10	Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. Prostate Cancer and Prostatic Diseases, 2021, , .	2.0	2
11	Protocol for GET FIT Prostate: a randomized, controlled trial of group exercise training for fall prevention and functional improvements during and after treatment for prostate cancer. Trials, 2021, 22, 775.	0.7	7
12	HIF1 and ID1 Interplay Confers Adaptive Survival to HIF1Î±-Inhibition. Frontiers in Cell and Developmental Biology, 2021, 9, 724059.	1.8	0
13	Examining developments in multicancer early detection: highlights of new clinical data from recent conferences. American Journal of Managed Care, 2021, 27, S347-S355.	0.8	4
14	Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. JAMA Oncology, 2020, 6, 217.	3.4	18
15	Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 316-323.	2.0	6
16	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. JCO Oncology Practice, 2020, 16, 811-819.	1.4	35
17	The DNA methylation landscape of advanced prostate cancer. Nature Genetics, 2020, 52, 778-789.	9.4	198
18	Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2020, 26, 4616-4624.	3.2	10

#	Article	IF	Citations
19	Autoantibody Landscape in Patients with Advanced Prostate Cancer. Clinical Cancer Research, 2020, 26, 6204-6214.	3.2	10
20	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA Network Open, 2020, 3, e2021692.	2.8	70
21	Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naÃ¯ve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. European Urology, 2020, 78, 347-357.	0.9	75
22	Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 931.e9-931.e16.	0.8	4
23	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	0.9	278
24	Feasibility and Acceptability of a Remotely Delivered, Web-Based Behavioral Intervention for Men With Prostate Cancer: Four-Arm Randomized Controlled Pilot Trial. Journal of Medical Internet Research, 2020, 22, e19238.	2.1	25
25	Novel blood-based early cancer detection: diagnostics in development. American Journal of Managed Care, 2020, 26, S292-S299.	0.8	14
26	Combining options in metastatic prostate cancer. Nature Reviews Urology, 2019, 16, 569-570.	1.9	1
27	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clinical Genitourinary Cancer, 2019, 17, 275-282.e1.	0.9	42
28	Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Molecular Cancer Research, 2019, 17, 1235-1240.	1.5	51
29	Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. European Urology Oncology, 2019, 2, 677-684.	2.6	22
30	Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. European Urology, 2019, 76, 562-571.	0.9	104
31	MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 531-538.	2.0	66
32	Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 52-63.	3.2	44
33	Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 694.	3.4	46
34	Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. Journal of Clinical Oncology, 2018, 36, 2492-2503.	0.8	477
35	Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precision Oncology, 2018, 2018, 1-14.	1.5	14
36	Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy. Nature Communications, 2018, 9, 4972.	5.8	40

#	Article	IF	Citations
37	Implementing a comprehensive translational oncology platform: from molecular testing to actionability. Journal of Translational Medicine, 2018, 16, 358.	1.8	35
38	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 2018, 174, 758-769.e9.	13.5	459
39	Effect of Increasing Levels of Web-Based Behavioral Support on Changes in Physical Activity, Diet, and Symptoms in Men With Prostate Cancer: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e11257.	0.5	9
40	Falls and Frailty in Prostate Cancer Survivors: Current, Past, and Never Users of Androgen Deprivation Therapy. Journal of the American Geriatrics Society, 2017, 65, 1414-1419.	1.3	66
41	Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. European Journal of Cancer, 2017, 81, 228-236.	1.3	76
42	CTâ€“Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. Journal of Vascular and Interventional Radiology, 2017, 28, 1073-1081.e1.	0.2	30
43	The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies. European Journal of Cancer, 2017, 87, 21-29.	1.3	26
44	Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. Lancet Oncology, The, 2017, 18, 1532-1542.	5.1	65
45	Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer. Anti-Cancer Drugs, 2017, 28, 120-126.	0.7	10
46	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	288
47	Enzalutamide in Men with Chemotherapy-naÃ¯ve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. European Urology, 2017, 71, 151-154.	0.9	306
48	Cyclooxygenaseâ€2 (<scp>COX</scp>â€2) inhibition for prostate cancer chemoprevention: doubleâ€blind randomised study of preâ€prostatectomy celecoxib or placebo. BJU International, 2017, 119, 709-716.	1.3	24
49	Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 40-47.	0.8	577
50	Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. Oncotarget, 2017, 8, 71447-71455.	0.8	23
51	Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget, 2016, 7, 52810-52817.	0.8	305
52	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. , 2016, 4, 92.		31
53	Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundationâ€“Supported West Coast Prostate Cancer Dream Team. European Urology Focus, 2016, 2, 469-471.	1.6	12
54	Raising the Bar for Therapeutic Trials in Advanced Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 2958-2960.	0.8	2

#	Article	IF	Citations
55	The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naÃ¯ve Metastatic Castration-resistant Prostate Cancer. European Urology, 2016, 70, 675-683.	0.9	70
56	Benefits of partnered strength training for prostate cancer survivors and spouses: results from a randomized controlled trial of the Exercising Together project. Journal of Cancer Survivorship, 2016, 10, 633-644.	1.5	104
57	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of Clinical Oncology, 2016, 34, 1402-1418.	0.8	1,089
58	Resistance Exercise Reduces Body Fat and Insulin During Androgen-Deprivation Therapy â€¨for Prostate Cancer. Oncology Nursing Forum, 2015, 42, 348-356.	0.5	50
59	Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. Clinical Genitourinary Cancer, 2015, 13, e191-e198.	0.9	9
60	Long-term Safety and Antitumor Activity in the Phase 1â€“2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. European Urology, 2015, 68, 795-801.	0.9	39
61	Bevicizumab and thrombosis: Some answers but questions remain. Cancer, 2015, 121, 975-977.	2.0	2
62	Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncology, The, 2015, 16, 509-521.	5.1	174
63	Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer Patients. Clinical Genitourinary Cancer, 2015, 13, e217-e221.	0.9	13
64	Resistance Training Reduces Disability in Prostate Cancer Survivors on Androgen Deprivation Therapy: Evidence From a Randomized Controlled Trial. Archives of Physical Medicine and Rehabilitation, 2015, 96, 7-14.	0.5	102
65	Carbohydrate-conjugated fluorescent silica nanoprobes for selective detection of galectin-1 and prostate cancer cells. Science Letters Journal, 2015, 4, .	0.0	1
66	Chemotherapy-Induced Monoamine Oxidase Expression in Prostate Carcinoma Functions as a Cytoprotective Resistance Enzyme and Associates with Clinical Outcomes. PLoS ONE, 2014, 9, e104271.	1.1	30
67	Sustained Complete Response to CTLA-4 Blockade in a Patient with Metastatic, Castration-Resistant Prostate Cancer. Cancer Immunology Research, 2014, 2, 399-403.	1.6	38
68	Pharmacotherapeutic Management of Metastatic, Castration-Resistant Prostate Cancer in the Elderly: Focus on Non-Chemotherapy Agents. Drugs and Aging, 2014, 31, 873-882.	1.3	13
69	Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. Expert Review of Anticancer Therapy, 2014, 14, 51-61.	1.1	1
70	Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer. Clinical Cancer Research, 2014, 20, 1306-1312.	3.2	19
71	Skeletal Response to Resistance and Impact Training in Prostate Cancer Survivors. Medicine and Science in Sports and Exercise, 2014, 46, 1482-1488.	0.2	84
72	Personalizing prostate cancer therapy: the way forward. Drug Discovery Today, 2014, 19, 1483-1487.	3.2	7

#	Article	IF	Citations
73	Review of Exercise Studies in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy Calls for an Aggressive Research Agenda to Generate High-Quality Evidence and Guidance for Exercise As Standard of Care. Journal of Clinical Oncology, 2014, 32, 2518-2519.	0.8	12
74	Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. New England Journal of Medicine, 2014, 371, 424-433.	13.9	2,456
75	Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 130-137.	0.9	27
76	Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism. Prostate, 2013, 73, 1028-1037.	1.2	52
77	Quality of Life After Sipuleucel-T Therapy: Results From a Randomized, Double-blind Study in Patients With Androgen-dependent Prostate Cancer. Urology, 2013, 82, 410-415.	0.5	17
78	Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials. European Urology, 2013, 63, 717-723.	0.9	104
79	The role of Câ€reactive protein in prostate cancer. Cancer, 2013, 119, 3262-3264.	2.0	6
80	C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 33-37.	0.8	57
81	Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nature Medicine, 2012, 18, 1359-1368.	15.2	682
82	Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study.. Journal of Clinical Oncology, 2012, 30, 25-25.	0.8	11
83	The safety of prostate biopsy procedures in the research setting: A 10-year multicenter experience.. Journal of Clinical Oncology, 2012, 30, 87-87.	0.8	0
84	Prostate Cancer and Vitamin D: What Does the Evidence Really Suggest?. Urologic Clinics of North America, 2011, 38, 333-342.	0.8	12
85	Vitamin D and Prostate Cancer. , 2011, , 221-249.		1
86	New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety. European Urology, 2011, 60, 279-290.	0.9	130
87	Toward predictors of survival in castrationâ€resistant prostate cancer. Cancer, 2011, 117, 3882-3884.	2.0	2
88	Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer. Clinical Cancer Research, 2011, 17, 4558-4567.	3.2	128
89	A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Anti-Cancer Drugs, 2010, 21, 433-438.	0.7	38
90	Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes and Control, 2010, 21, 1297-1303.	0.8	48

#	Article	IF	Citations
91	Phase 1/2 study of preoperative docetaxel and mitoxantrone for highâ€risk prostate cancer. Cancer, 2010, 116, 1699-1708.	2.0	38
92	CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxelâ€induced cytotoxicity. Prostate, 2010, 70, 433-442.	1.2	98
93	Histologic Changes Associated With Neoadjuvant Chemotherapy Are Predictive of Nodal Metastases in Patients With High-Risk Prostate Cancer. American Journal of Clinical Pathology, 2010, 133, 654-661.	0.4	58
94	Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer. Cancer Research, 2010, 70, 7992-8002.	0.4	313
95	Acupuncture for Hot Flashes in Patients With Prostate Cancer. Urology, 2010, 76, 1182-1188.	0.5	47
96	Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1â€“2 study. Lancet, The, 2010, 375, 1437-1446.	6.3	972
97	Calcitriol and Vitamin D Analogs. , 2010, , 287-302.		0
98	Prostate Cancerâ€“Associated Gene Expression Alterations Determined from Needle Biopsies. Clinical Cancer Research, 2009, 15, 3135-3142.	3.2	15
99	Optimal timing of chemotherapy in androgen independent prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 97-100.	0.8	5
100	Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer. Science, 2009, 324, 787-790.	6.0	1,955
101	Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer. Cancer, 2008, 112, 326-330.	2.0	91
102	Câ€reactive protein as a prognostic marker for men with androgenâ€independent prostate cancer. Cancer, 2008, 112, 2377-2383.	2.0	98
103	Patientâ€physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer. Cancer, 2008, 113, 2205-2214.	2.0	102
104	A phase II study of highâ€dose calcitriol combined with mitoxantrone and prednisone for androgenâ€independent prostate cancer. BJU International, 2008, 102, 1601-1606.	1.3	35
105	Southwest Oncology Group Phase II Study of Ispinesib in Androgen-Independent Prostate Cancer Previously Treated with Taxanes. Clinical Genitourinary Cancer, 2008, 6, 103-109.	0.9	46
106	Southwest Oncology Group Phase II Study of Irinotecan in Patients with Advanced Transitional Cell Carcinoma of the Urothelium that Progressed After Platinum-Based Chemotherapy. Clinical Genitourinary Cancer, 2008, 6, 36-39.	0.9	27
107	Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology, 2008, 26, 1148-1159.	0.8	1,960
108	The Iroquois Homeobox Gene 5 Is Regulated by 1,25-Dihydroxyvitamin D3 in Human Prostate Cancer and Regulates Apoptosis and the Cell Cycle in LNCaP Prostate Cancer Cells. Clinical Cancer Research, 2008, 14, 3562-3570.	3.2	55

#	Article	IF	Citations
109	Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators. Journal of Clinical Oncology, 2007, 25, 669-674.	0.8	296
110	Molecular Alterations in Prostate Carcinomas that Associate with In vivo Exposure to Chemotherapy: Identification of a Cytoprotective Mechanism Involving Growth Differentiation Factor 15. Clinical Cancer Research, 2007, 13, 5825-5833.	3.2	60
111	American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Nonhormonal Therapy for Men With Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer. Journal of Clinical Oncology, 2007, 25, 5313-5318.	0.8	65
112	Diethylstilbestrol and docetaxel. Cancer, 2007, 110, 996-1002.	2.0	17
113	The hazards of intermediate endpoints. Cancer, 2007, 110, 1877-1879.	2.0	7
114	Prostate cancer survival is dependent on season of diagnosis. Prostate, 2007, 67, 1362-1370.	1.2	48
115	Darbepoetin Alfa Administered Every 4 Weeks for Anemia in Patients with Advanced Prostate Cancer. Clinical Genitourinary Cancer, 2007, 5, 329-333.	0.9	5
116	Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemotherapy and Pharmacology, 2007, 59, 581-587.	1.1	42
117	Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Investigational New Drugs, 2007, 25, 565-570.	1.2	49
118	Testosterone Loss and Estradiol Administration Modify Memory in Men. Journal of Urology, 2006, 175, 130-135.	0.2	110
119	Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 254-259.	0.8	29
120	Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study. Anti-Cancer Drugs, 2006, 17, 1075-1079.	0.7	4
121	High dose calcitriol may reduce thrombosis in cancer patients. British Journal of Haematology, 2006, 135, 392-394.	1.2	76
122	Parenteral Estrogens for Prostate Cancer: Can a New Route of Administration Overcome Old Toxicities?. Clinical Genitourinary Cancer, 2006, 5, 198-205.	0.9	6
123	Southwest oncology group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer, 2006, 106, 2624-2629.	2.0	33
124	The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer. Cancer, 2006, 107, 489-496.	2.0	37
125	Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer. Journal of Lipid Research, 2006, 47, 349-355.	2.0	21
126	Effect of Calcitriol on Prostate-Specific Antigen In vitro and in Humans. Clinical Cancer Research, 2006, 12, 2812-2816.	3.2	14

#	Article	IF	Citations
127	Vitamin D Analogs and Their Role in Prostate Cancer. Translational Medicine Series, 2006, , 257-279.	0.0	0
128	Calcitriol in the treatment of prostate cancer. Anticancer Research, 2006, 26, 2647-51.	0.5	39
129	ASCENT: The androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU International, 2005, 96, 508-513.	1.3	40
130	Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer, 2005, 103, 717-723.	2.0	48
131	Rationale for the development and current status of calcitriol in androgen-independent prostate cancer. World Journal of Urology, 2005, 23, 28-32.	1.2	29
132	Pharmacokinetics and Tolerability of a Single Dose of DN-101, a New Formulation of Calcitriol, in Patients with Cancer. Clinical Cancer Research, 2005, 11, 7794-7799.	3.2	46
133	Improved Detection of Prostate Cancer Using Classification and Regression Tree Analysis. Journal of Clinical Oncology, 2005, 23, 4322-4329.	0.8	95
134	HIGH DOSE PULSE CALCITRIOL, DOCETAXEL AND ESTRAMUSTINE FOR ANDROGEN INDEPENDENT PROSTATE CANCER: A PHASE I/II STUDY. Journal of Urology, 2005, 174, 888-892.	0.2	40
135	Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005?. European Journal of Cancer, 2005, 41, 954-964.	1.3	12
136	Statins and Prostate Cancer Risk: A Case-Control Study. American Journal of Epidemiology, 2005, 162, 318-325.	1.6	217
137	Phase I Study of Weekly Mitoxantrone and Docetaxel before Prostatectomy in Patients with High-Risk Localized Prostate Cancer. Clinical Cancer Research, 2004, 10, 1306-1311.	3.2	33
138	How Accurate Is Clinician Reporting of Chemotherapy Adverse Effects? A Comparison With Patient-Reported Symptoms From the Quality-of-Life Questionnaire C30. Journal of Clinical Oncology, 2004, 22, 3485-3490.	0.8	475
139	Polymorphisms of GSTT1 and related genes in head and neck cancer risk. Head and Neck, 2004, 26, 63-70.	0.9	34
140	Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma. Cancer, 2004, 100, 758-763.	2.0	21
141	Prevention and management of prostate cancer chemotherapy complications. Urologic Clinics of North America, 2004, 31, 367-378.	0.8	4
142	PROGNOSTIC VALUE OF ANEMIA IN NEWLY DIAGNOSED METASTATIC PROSTATE CANCER: A MULTIVARIATE ANALYSIS OF SOUTHWEST ONCOLOGY GROUP STUDY 8894. Journal of Urology, 2004, 172, 2213-2217.	0.2	30
143	Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy. Urology, 2004, 63, 342-347.	0.5	31
144	High-Dose Calcitriol and Carboplatin in Metastatic Androgen-Independent Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 535-541.	0.6	44

#	Article	IF	Citations
145	Calcitriol in cancer treatment: from the lab to the clinic. Molecular Cancer Therapeutics, 2004, 3, 373-81.	1.9	100
146	Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 2225-32.	1.1	14
147	High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer, 2003, 97, 1217-1224.	2.0	120
148	Phase II Study of Abarelix Depot for Androgen Independent Prostate Cancer Progression During Gonadotropin-Releasing Hormone Agonist Therapy. Journal of Urology, 2003, 169, 1738-1741.	0.2	28
149	Weekly Docetaxel in Elderly Patients with Prostate Cancer: Efficacy and Toxicity in Patients Aged â‰¥ 70 Years Compared with Patients Aged < 70 Years. Clinical Prostate Cancer, 2003, 2, 167-172.	2.1	47
150	Development of weekly high-dose calcitriol based therapy for prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 399-405.	0.8	37
151	Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer. Journal of Clinical Oncology, 2003, 21, 123-128.	0.8	245
152	Docetaxel (TaxotereÂ®) in the treatment of prostate cancer. Expert Review of Anticancer Therapy, 2003, 3, 261-268.	1.1	37
153	Simplified Assessment of Compliance With and Acceptability of Dietary Calcium Restriction in Patients Treated With High Dose Calcitriol for Advanced Cancer. Topics in Clinical Nutrition, 2003, 18, 61-70.	0.2	0
154	A New Formulation of Calcitriol (DN-101) for High-Dose Pulse Administration in Prostate Cancer Therapy. Reviews in Urology, 2003, 5 Suppl 3, S38-44.	0.9	3
155	Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer. Current Urology Reports, 2002, 3, 232-238.	1.0	2
156	SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION: A RARE COMPLICATION OF PROSTATE CANCER. Journal of Urology, 2001, 166, 1386-1386.	0.2	8
157	Allogeneic stem-cell transplantation in renal-cell carcinoma. Current Oncology Reports, 2001, 3, 433-437.	1.8	3
158	Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate, 2001, 49, 263-266.	1.2	69
159	A Phase I trial of pulse calcitriol in patients with refractory malignancies. Cancer, 2001, 91, 2431-2439.	2.0	116
160	Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Seminars in Oncology, 2001, 28, 49-55.	0.8	53
161	A Phase I trial of pulse calcitriol in patients with refractory malignancies. , 2001, 91, 2431.		3
162	Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Seminars in Oncology, 2001, 28, 49-55.	0.8	148

#	Article	IF	Citations
163	SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION:. Journal of Urology, 2001, , 1386.	0.2	1
164	Chemotherapy for hormone-refractory prostate cancer: Beauty is in the eye of the beholder. Prostate, 2000, 45, 184-193.	1.2	33
165	Genetic polymorphisms in head and neck cancer risk. Head and Neck, 2000, 22, 609-617.	0.9	64